Discover outperforming stocks and invest smarter with Top Smart Score StocksFilter, analyze, and streamline your ...

Mountainfield Venture Partners and Chengdu, China-based Keymed Biosciences Co. Ltd have partnered to form San Diego-based Timberlyne Therapeutics, which will progress Keymed’s CD-38 monoclonal ...

CHENGDU, China, Dec. 23, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the ...

Keymed Biosciences, Inc. (HK:2162) has released an update. Keymed Biosciences Inc. has unveiled promising data from its phase I/II clinical study of CM336, a bispecific antibody for treating ...

This approval marks a significant step for Keymed, showcasing its potential in the pharmaceutical market. For further insights into HK:2162 stock, check out TipRanks’ Stock Analysis page.

CHENGDU, China, Dec. 23, 2024 /PRNewswire/ -- Keymed Biosciences Inc. (HKEX: 02162) today announced the National Medical Products Administration (the "NMPA") of China has recently approved the ...

U.S.-based biotech builder Mountainfield Venture Partners and China’s Keymed Biosciences have launched a new company armed with $180 million in series A funds and a clinical-stage CD38-targeting ...